EQL Pharma AB (publ) announced that the company's long-term financial goals remain unchanged, as does the sales forecast for the full year 2023/24, where they forecast growth of around 30%.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
51.4 SEK | +2.39% |
|
+3.84% | +53.89% |
06-12 | EQL Pharma Receives Approval for Listing to Nasdaq Stockholm Main Market | MT |
05-15 | Transcript : EQL Pharma AB, Q4 2024 Earnings Call, May 15, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+53.89% | 143M | |
-39.87% | 13.73B | |
-42.46% | 9.46B | |
-21.93% | 7.11B | |
-6.09% | 5.88B | |
+78.71% | 4.79B | |
-4.09% | 4.54B | |
+3.97% | 4.44B | |
-21.06% | 4.35B | |
-18.19% | 2.64B |
- Stock Market
- Equities
- EQL Stock
- News EQL Pharma AB
- EQL Pharma AB Provides Sales Guidance for the Year 2023/24